XML 61 R27.htm IDEA: XBRL DOCUMENT v3.24.1
Share Capital (Tables)
12 Months Ended
Dec. 31, 2023
Stockholders' Equity Note [Abstract]  
Schedule of the effect of share-based compensation on the statements of operations
 
   
Year ended
   
Year ended
   
Year ended
 
   
December 31,
   
December 31,
   
December 31,
 
   
2023
   
2022
   
2021
 
   
USD thousands
   
USD thousands
   
USD thousands
 
Research and development
   
407
     
448
     
137
 
General and administrative
   
1,084
     
2,763
     
1,882
 
                         
Total share-based compensation expenses
   
1,491
     
3,211
     
2,019
 
Schedule of number and weighted average exercise prices of option
   
Weighted average
exercise price
   
Number
of options
   
Weighted
average
remaining contractual life (in years)
   
Weighted
average
exercise price
   
Number
of options
   
Weighted
average
remaining contractual life (in years)
 
   
2022
   
2022
   
2022
   
2021
   
2021
   
2021
 
Outstanding at January 1
   
0.38
     
27,003,260
     
8.12
     
0.07
     
10,455,580
     
7.8
 
Acquired in Merger
   
-
     
-
     
-
             
609,535
         
Exercised
   
0.07
     
(1,970,000
)
   
-
     
0.08
     
(134,220
)
   
-
 
Forfeited
   
0.32
     
(1,240,120
)
   
-
     
1.25
     
(1,712,275
)
   
-
 
Granted
   
0.16
     
11,398,400
     
7.8
     
0.62
     
17,784,640
     
9.79
 
                                                 
Outstanding at December 31
   
0.33
     
35,191,540
     
7.42
     
0.38
     
27,003,260
     
8.12
 
 
   
Weighted average
exercise price
   
Number
of options
   
Weighted
average
remaining contractual life (in years)
   
Weighted
average
exercise price
   
Number
of options
   
Weighted
average
remaining contractual life (in years)
 
   
2023
   
2023
   
2023
   
2022
   
2022
   
2022
 
Outstanding at January 1
   
0.33
     
35,191,540
     
7.42
     
0.38
     
27,003,260
     
8.12
 
Exercised
   
-
     
-
     
-
     
0.07
     
(1,970,000
)
   
-
 
Forfeited
   
0.39
     
(20,373,620
)
   
-
     
0.32
     
(1,240,120
)
   
-
 
Granted
   
0.07
     
15,055,180
     
5.86
     
0.16
     
11,398,400
     
7.8
 
                                                 
Outstanding at December 31
   
0.16
     
29,873,100
     
5.99
     
0.33
     
35,191,540
     
7.42
 
Schedule of assumptions used to calculate the fair value of the options
 
   
2023 grants
 
Weighted average share price (in U.S. dollar)(a)
   
0.07
 
Exercise price (in U.S. dollar)
   
0.06-0.09
 
Expected life of options (in years)(b)
   
4.53-9.46
 
Expected volatility(c)
   
97.79%-112.94
%
Risk-free interest rate(d)
   
3.71%-4.43
%
Dividend yield
   
0
%